J&J Duragesic “Black Box” Adds Fentanyl Abuse Warning

Revised labeling also narrows the indicated population and warns about drug-drug interactions with CYP 3A4 inhibitors. FDA notes J&J is in “discussions with the agency regarding establishment of a risk management program.” Labeling changes were approved one week after Duragesic generics entered the market.